Dimethylsulfoxide (DMSO), which is widely used as a cryoprotectant for hematopoietic stem cells (HSC), has considerable toxicity for both the thawed cells and the patient. The aim of this study was to evaluate the cryoprotective potential of trehalose in comparison to DMSO for human HSC. Human bone marrow (BM) and peripheral blood stem cells (PBSC) of volunteer donors were cryopreserved in the presence of different concentrations of trehalose with and without insulin, as well as with DMSO 10%. After thawing to 371C colony-forming unit (CFU) assays were performed. Long-term marrowcultures (LTMC) were established and used for the detection of long-term culture-initiating cells (LTCIC). The total amount of CFUs detected was 1047134 (mean7s.d.) in DMSO-preserved cells and 179734 in trehalose-protected cells. For LTMC the best feeder layer proved to be fresh human BM and the most useful concentration of trehalose was 0.5 M. Using these culture conditions we could detect after 5 weeks LTMC a total of 172728 CFUs for trehalose-protected cells and 170752 for DMSO-preserved cells. In conclusion, trehalose exerts a similar cryoprotective potential for hematopoietic progenitor and stem cells like DMSO and could possibly replace DMSO at least in part as cryoprotectant in the setting of hematopoietic cell transplantation.
poietic stem cells
Bone marrow transplantation (BMT) and mobilized peripheral stem cell transplantation (SCT) are highly effective treatment options for a variety of hematological and neoplastic diseases. 1 In autologous and rarely in allogeneic BMT or SCT, as well as in cord blood transplantation (CBT), 2 the graft has to be cryoconserved in liquid nitrogen prior to transplantation. Dimethylsulfoxide (DMSO) is most widely used as the cryoprotectant. [1] [2] [3] [4] [5] However, DMSO has been reported to exert toxic effects on hematopoietic stem cells (HSC) at room temperature. Therefore, the graft has to be infused immediately after thawing at a low temperature. 1, 6 Transplantation of DMSO-cryopreserved cells is frequently associated with serious side effects, such as vomiting, acute abdominal pain, dyspnea, and hemoglobinuria, [3] [4] [5] 7 which are possibly attributable to the infusion of DMSO. Rarely, even more severe and potentially lethal complications such as highgrade heart block II1-III1, 5, 8 cardiac arrest, 9 respiratory decompensation, 5 acute renal failure, 10 or severe neurological complications 11 occurred. Several investigations indicate that DMSO may cause activation of the complement cascade in human serum that could contribute to DMSOrelated side effects. 7, [12] [13] [14] Therefore, the development of a DMSO-free method of cryopreservation might improve the safety of hematopoietic cell transplantation by both, by reducing the side effects for the patient and by avoiding toxic effects on the cryoprotected cells.
For successful engraftment the survival of early hematopoietic progenitor cells including HSC is essential. 1, [15] [16] [17] To distinguish between mature hematopoietic cells and precursor cells, the methylcellulose assay is a quantitative, simple, reliable, and reproducible method. [18] [19] [20] Especially the growing of CFU-GM and CFU-GEMM suggest the existence of early precursor cells, even HSC. The most reliable in vitro method, however, to evaluate the existence of HSC in the sample is the long-term marrow culture (LTMC). 18, [21] [22] [23] [24] [25] This study was undertaken to evaluate the cryoprotective potential of trehalose, a natural cryoprotectant produced by various microorganisms, as a single agent for human HSC. For this purpose we cryopreserved bone marrow/peripheral blood stem cells (BM/PBSC) with trehalose without addition of DMSO and compared it to DMSO-protected BM/PBSC using viability count, CFU-assays, and LTMC.
Materials and methods

Experimental design
We compared BM and PBSCs, cryopreserved with either DMSO or various concentrations of trehalose with or without addition of insulin. Viability after thawing was determined using trypan blue exclusion. The thawed cells were evaluated by their potential to generate CFUs in 2-week methylcellulose-assays according to standard procedures. 19, 20 To distinguish between LTCIC and more mature progenitors of hematopoiesis we used LTMC. We established a method for LTMC for cryopreserved BM modifying methods described for fresh BM. 18, [21] [22] [23] [25] [26] [27] For this purpose we compared different feeder layers for their ability to support LTCIC in LTC with BM cryopreserved with the various cryomedia described above. The modifications giving the best results were used to compare DMSO-and trehalose-cryoprotected BM on their potential to generate LTCICs.
Marrow cells
Human BM was obtained from healthy volunteer donors after informed consent. It was collected under general anesthesia from the iliac crest and immediately mixed with 10 vol% ACD-A and 100 IU/ml Heparin. After standard filtration procedures the marrow was collected in plastic transfer bags. Samples taken from these bags were used in the experiments.
PBSCs
PBSCs were collected by leucapheresis from patients (five patients with breast cancer, two CML patients, one AML patient) or from healthy volunteer donors (n ¼ 7). Mobilizing procedures for patients consisted of disease-specific chemotherapy followed by subcutaneous injections of 5 mg/ kg/day G-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA). Healthy volunteer donors were mobilized at steady state by subcutaneous injections of 5 mg/kg/day G-CSF for 5-7 days. Peripheral blood CD34 þ cell counts were monitored and leukapheresis was performed using a Fenwal CS 3000 cell separator (Baxter, Mu¨nchen-Unterschleiheim, Germany) when the CD34 þ cell count rose above 10/ml. The citrated apheresis product was centrifuged at 1100 rpm for 10 min and the cells were resuspended in RPMI 1640 medium (Gibco BRL, Paisley, UK).
Cryopreservation and thawing
All manipulations of the BM and PBSCs were performed at 41C under sterile conditions. After counting the number of mononuclear cells (MNC), 1 ml BM containing a median of 2 Â 10 7 (1.7-2.9 Â 10 7 ) MNC, or 0.5 ml PBSCs containing a median of 1.7 Â 10 7 MNC (0.8-8.4 Â 10
7
) per freezing vial were mixed with an equal volume of freezing medium. The freezing media used were DMSO 10% (final concentration) or various concentrations of trehalose (1, 0.5, 0.25M; final concentrations) with or without addition of insulin (0.25 IU/ml; final concentration). The rationale for the addition of insulin was to try to enhance the cellular uptake of trehalose, since insulin-like peptides lowered circulating trehalose levels in insects. 28 Immediately after the addition of the freezing media the samples were frozen under controlled conditions to À801C using a TRA-14 programmed freezing unit (Consarctic, Scho¨llkrippen, Germany) and stored in liquid nitrogen at À1961C until final use. Cryopreserved BM/PBSC were rapidly thawed in a 371C water bath and immediately diluted 1 : 5 in RPMI 1640 medium. MNC were obtained by density centrifugation over Ficoll-Hypaque (density 1.077 g/cm 2 ; Biochrom, Berlin, Germany) at 400 g and washed by resuspension in RPMI 1640 and centrifugation.
Viability
The viability of the thawed cells was determined in 15 samples for each freezing condition by trypan blue exclusion, reading the results immediately after adding the dye.
Methylcellulose assay
Freshly thawed cells were analyzed in clonogenic assays. In total, 3 ml of 0.9% methylcellulose (MC) in Iscove's modified Dulbecco's medium (IMDM), enriched with 50 ng/ml stem cell factor, 10 ng/ml interleukin 3, 10 ng/ml GM-CSF and 3 U/ml erythropoietin (Methocult GF H4434; Stem Cell Technologies, Vancouver, Canada) were mixed with 3 Â 10 5 MNC/ml and plated in two 35 mm Petri dishes (Greiner, Frickenhausen, Germany). These cultures were incubated at 371C, 5% CO 2 in a humidified atmosphere for 2 weeks. After this time, the colonies were scored by inverted microscopy for colony-forming units granulocyte (CFU-G), colony-forming units macrophage (CFU-M), burst-forming units erythroid (BFU-E), colonyforming units erythroid (CFU-E), colony-forming units granulocyte-macrophage (CFU-GM), and colonyforming units granulocyte-erythroid-monocyte-macrophage (CFU-GEMM).
Long-term marrow culture LTMC were established using modifications of methods described for fresh BM. 18, [21] [22] [23] [25] [26] [27] Different feeder-layers, namely from fresh human BM, 15, 16, 18, [22] [23] [24] [25] from the murine cell line M2 10 B4, 25, 27, 29, 30 and from the human cell line 88/5 26, 31 were tested for their ability to support LTCIC in LTMC generated from BM cryopreserved as described above.
Feeder-layer from fresh human BM. This was generated by density gradient centrifugation of 4-10 ml fresh BM over ficoll hypaque. After washing and counting 3 Â 10 7 MNC suspended in 20 ml MyeloCult-media (Stem Cell Technologies, Vancouver, Canada) were plated in 75 cm 2 tissue culture flasks (Corning, NJ, USA). At a weekly exchange of 15 ml media the cultures were maintained between 2.5 and 4 weeks, until the layer was confluent. After trypsinizing and replating in 35 mm Petri dishes (1 Â 10 5 cells per dish), the cells were cultured for 3 more days. After reaching confluence they were irradiated with 16 Gy.
Feeder-layer from the human cell-line 88/5. After thawing at 371C 1 Â 10 6 cells were suspended in 15 ml MyeloCult media, plated in 75 cm 2 tissue culture flasks and maintained for 1 week. After trypsinization and replating in Petri dishes (1 Â 10 5 cells per dish), the cells were irradiated with 15 Gy the same day.
Feeder-layer from the murine cell-line M2 10 B4. M2 10 B4 cells were thawed, washed, and 2 Â 10 6 cells were resuspended in 10 ml RPMI 1640 medium supplemented with L-Glutamine þ 10% FCS þ 1% penicillin-streptomycin and plated in 25 cm 2 tissue culture flasks (Corning, NJ, USA). After 4 days 5 ml media were exchanged and after further 4 days the cells were trypsinized and replated in Petri dishes (2 Â 10 5 cells per dish). After an additional 3 to 4 days after reaching confluence they were irradiated with 60 Gy.
Stem cell inoculum and LTMC. All experiments were performed with three different samples. Cryopreserved BM was thawed and 2 Â 10 7 MNC were resuspended in 10 ml PBS þ 10% FCS and incubated at 371C and 5% CO 2 in 90 mm Petri dishes for 90 min and the nonadherent cells were centrifuged for 10 min at 1200 rpm and resuspended in 2 ml MyeloCult media and plated on the irradiated feederlayer. These cultures were maintained for 5 weeks at 371C, 5% CO 2 in a humidified atmosphere with weekly exchanges of 1 ml of media. After 5 weeks the nonadherent cells were harvested and the feeder-layer cells were separated by trypsination and, depending on the experiment, saved separately or together with the nonadherent fraction. After centrifugation (10 min, 1200 rpm, 41C) and resuspension in IMDM (Gibco BRL, Paisley, UK) various cell dilutions (1 : 5 to 1 : 100) were analyzed by methylcellulose assays as described.
Statistics
For direct comparisons a two-tailed student's t-test was employed. A P-value of 0.05 was assumed to be significant.
Results
Viability of cryopreserved hematopoietic cells from BM or PBSC
DMSO-cryopreserved cells exhibited the best median viability-rate (33%, range 12-69%) after thawing. Comparable results could be achieved with trehalose 0.5 M without insulin (32%, range 14-50%) and trehalose 0.5 M with insulin 0.25 IU/ml (30%, range 14-55%). The other concentrations of trehalose with or without added insulin showed slightly lower viability rates after thawing: Trehalose 1 M with insulin (25%, range 0-55%), trehalose 1 M without insulin (21%, range 7-64%), trehalose 0.25 M with insulin (19%, range 7-33%), trehalose 0.25 M without insulin (17%, range 10-38%). By statistical analysis the differences between DMSO and trehalose 1 M with insulin (P ¼ 0.01) or trehalose 0.25 M without (P ¼ 0.003) or with insulin (P ¼ 0.000) were significant. Within the trehalose cohorts, trehalose 0.5 M was significantly superior to trehalose 0.25 M (P ¼ 0.002). The addition of insulin had no significant effect on viability at any trehalose concentration. As expected, the control group frozen under the same conditions with sodium chloride 0.9% exhibited a viability-rate of 0%. No differences could be observed with respect to the stem cell source or freezing concentration of MNC.
Methylcellulose assays
As depicted in Figure 1 , hematopoietic cells cryopreserved with any trehalose-based freezing regimen produced at least comparable numbers of colonies as cells cryopreserved with DMSO. By distinguishing between CFU-GM, CFU-GEMM, BFU-E, CFU-E, CFU-G and CFU-M similar results could be obtained. The addition of insulin did not enhance the numbers of colonies in general (Table 1) . Again, no differences could be observed with respect to the stem cell source.
Feeder-layers supporting LTMC
The generation of colonies after LTMC with DMSOcryopreserved BM revealed a superiority of the feeder-layer from fresh BM as compared to M2 10B4 feeder-layer, independently of the numbers of cells (3.3 Â 10 5 or 6.6 Â 10 5 ) inoculated and the cell fraction investigated (Figure 2) . In a second series of experiments, which compared the cryopotential of DMSO 10% with various trehalose-based cryomedia, we used 88/5 feeder-layer, in addition to fresh human BM and the layer from the murine M2 10B4 cell line. To exclude additional variables cells from one cryovial were equally distributed among three Petri dishes each prepared with a different feeder-layer. This experiment revealed comparable results for DMSOand trehalose-cryopreserved BM and confirmed the superiority of feeder-layer from fresh human BM as compared to M2 10B4 feeder-layer. However, 88/5 feeder-layer may be a similar effective alternative ( Table 2 ). The addition of insulin did not improve the results.
Generation of LTCIC after cryopreservation of BM with DMSO 10% or trehalose 0.5 M Based on the previous results, LTMC were performed with feeder-layer from fresh human BM and an inoculum of 5 Â 10 5 cells. We could detect a similar survival of LTCIC in DMSO (170752)-and trehalose (172728)-cryopreserved BM. We were unable to detect any significant differences on the generation of the committed colonies BFU-E, CFU-E, CFU-M, CFU-G, CFU-GM, and CFU-GEMM by means of the student's t-test (Table 3) . Discussion
Trehalose is a disaccharide produced by several microorganisms, who can even survive freeze-drying. [32] [33] [34] Its cryoprotective potential has been evaluated in a variety of tissues and cells that do not produce trehalose themselves. [35] [36] [37] The addition of trehalose to DMSO-based cryomedia, for example, resulted in a higher viability rate of cryopreserved pancreas-tissue 38 and increased colony formation of cryopreserved human HSC derived from cord blood and fetal liver. 39 Similarly, the combination of DMSO and trehalose for cryoprotection of hematopoietic cells derived from cord blood resulted in increased numbers of LTCIC. These cells also retained the potential to multilineage engraftment in nonobese diabetic-SCID mice. 40 However, in these studies, trehalose alone failed to exert any significant cryoprotective potential. By contrast, in our studies, which were also undertaken in small volume cryogenic vials, we could show that trehalose has a similar potential as DMSO to protect early precursors of hematopoiesis during freeze-thawing. This difference might be explained by two variations in the experimental design. First, we established a method for LTMC with DMSO-and trehalose-cryopreserved BM by modifying described methods for fresh BM. We compared three different as suitable described feeder-layers: layer from Table 2 Mean total number of CFUs from LTMC with BM cells cryopreserved with various cryomedia (1 : 50 dilution), using different feeder-layers (n ¼ 3) In our experiments the layer from fresh human BM exerted by far the best results, while cultures with M2 10B4, which was used by Zhang and co-workers 40 actually produced the lowest number of colonies ( Figure 2 ; Table 2 ). In addition, we also compared different concentrations of trehalose. Trehalose 0.5 M and 1 M produced slightly better results than trehalose 0.25 M. Based on our LTMC experiments we used higher concentrations of trehalose, namely 0.5 M, equaling an 18% solution, for the LTCIC assay. Using both modifications our experiments revealed a similar survival of LTCIC in 10% DMSO-and 0.5 M trehalosecryopreserved BM.
Interestingly, the viability of trehalose-cryopreserved cells was lower after thawing to 371C (2576%) than the viability of DMSO-protected cells (34714%). However, in methyl-cellulose assays the total amount of CFUs from trehalose-protected cells was higher (179734) than from DMSO-preserved cells (1047134), suggesting a higher quality of trehalose-protected hematopoietic precursor cells and a lower toxicity of this cryoprotectant for these cells.
Although other strategies to minimize DMSO toxicity, like lowering its concentration to 5% with or without addition of hydroxyethylstarch or washing the graft prior to transplantation are under investigation, we nevertheless feel that trehalose might be a valuable alternative or additive to DMSO for cryopreservation of HSC. Especially, in haploidentical or in CBT where the number of infused stem cells seems to be critical, the combination of both cryoprotectants might have a special advantage. In in vivo experiments in rodents no obviously trehalose-related adverse events have been observed. 40 However, as trehalose is not a physiological disaccharide for man, further experiments are needed prior to its clinical use.
